Novo Nordisk's newly launched Wegovy weight-loss pill demonstrates promising early performance in the United States. Initial prescription data reveals about 3,071 retail prescriptions filled in the first four days following its January 5 launch. This marks the debut of the first oral GLP-1 weight-loss drug on the market.
Stock Boost and Strategic Launch
Following the positive news, Novo Nordisk's shares surged 6.5%, hitting their highest level since September. The company prioritizes the US rollout to sidestep supply constraints, targeting cash-paying patients via major pharmacies and telehealth services.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Intensifying Competition with Eli Lilly
The pill bolsters Novo's efforts to counter US rival Eli Lilly amid rising competition. An FDA decision on Lilly's experimental oral pill looms by April. While early data is preliminary, analysts warn of potential impacts from pricing and insurance shifts.
Prescription Projections
- UBS projects that exceeding 400,000 first-quarter prescriptions could match Lilly's Zepbound and surpass Wegovy's injectable launch.
- Estimates suggest the pill may generate around $1 billion in sales this year with first-mover edge.
Though injectables will dominate, experts anticipate oral GLP-1 options will broaden access for needle-averse patients, expanding the weight management market.
